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INTRODUCTION:  Intravesical  BCG-instillation  for bladder  cancer  is considered  safe  but is  not  without  risk.
While  most  side-effects  are  localised  and  self-limiting,  the development  of  secondary  vascular  pathology
is  a rare  but  signiﬁcant  complication.
PRESENTATION OF  CASE:  A 77-year-old  male  presented  with  a mycotic  abdominal  aortic  aneurysm  and
associated  aorto-enteric  ﬁstula  18  months  after  receiving  intravesical  BCG-instillations  for early  stage
transitional  cell  carcinoma.
DISCUSSION: Response  rates  to intravesical  BCG  for  early  stage  transitional  cell  carcinoma  are  high.  The
procedure  produces  a localised  inﬂammatory  response  in  the  bladder  but the  exact  mechanism  of  action
is  unclear.  The  treatment  is  generally  well  tolerated  but BCG-sepsis  and  secondary  vascular  complications
have  been  documented.
Mycotic abdominal  aortic  aneurysm  with  associated  aorto-enteric  ﬁstula  secondary  to  BCG  is  very
rare.  Few  examples  have  been  documented  internationally  and the  extent  of corresponding  research  and
associated  management  proposals  is  limited.
Surgical options  include  in  situ  repair  with  prosthetic  graft,  debridement  with  extra-anatomical  bypass
and,  occasionally,  endovascular  stent  grafting.  Recommended  medical  therapy  for systemic  BCG  infection
is  Isoniazid,  Rifampicin  and  Ethambutol.
CONCLUSION: Current  screening  methods  must  be updated  with  clariﬁcation  regarding  duration  of  anti-
tuberculous  therapy  and  impact  of  concomitant  anti-tuberculous  medication  on  the  therapeutic  action  of
intravesical  BCG.  Long-term  outcomes  for patients  post graft repair  for  mycotic  aneurysm  are  unknown
and  more  research  is  required  regarding  the susceptibility  of  vascular  grafts  to mycobacterial  infection.
Recognition  of  the  risks  associated  with  BCG-instillations,  even  in  immunocompetent  subjects,  is
paramount  and  must  be considered  even  several  months  or  years  after  receiving  the therapy.
gical © 2012 Sur
. Introduction
Intravesical BCG is increasingly used as an adjunct therapy in the
reatment of transitional cell carcinoma of the bladder.1 The proce-
ure is generally considered safe but side-effects, most commonly
ever and malaise, occur. Haematuria caused by local secondary
ranulomatous inﬂammatory changes in the bladder as well as
otentially fatal BCG-sepsis have also been documented.3
The development of secondary vascular pathology is a rare but
igniﬁcant complication. Here we report a case in which a patient
resented with a mycotic abdominal aortic aneurysm and associ-
ted aorto-enteric ﬁstula, 18 months after receiving intra-vesical
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BCG-installations for early stage transitional cell carcinoma. Pro-
posed changes to current screening protocols are also explored.
2.  Case report
A  77-year-old male presented to the emergency department
with acute onset peri-umbilical pain radiating through to his
back, which was  exacerbated by lying ﬂat and associated with
nausea and vomiting. There were no past episodes of similar
pain and the patient denied any gastrointestinal or urologi-
cal symptoms or any lower limb neurovascular problems. He
was a smoker of 35 pack-years and consumed 50 units of
alcohol per week, no further cardiovascular risk factors were
identiﬁed.
Open access under CC BY-NC-ND license.Two years before, the patient had been diagnosed with super-
ﬁcial transitional cell carcinoma of the bladder (G1pTa), for which
he underwent initial trans-urethral resection and subsequent BCG
therapy due to recurrence. Past medical history also included
 BY-NC-ND license.
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Fig. 1. Abdominal CT with aortic aneurysm protocol demonstrating haematoma
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aneurysms are rare. Fifty percent of mycotic aneurysms secondarynto  the right psoas muscle (i) and a potential aorto-duodenal communication (ii).
hronic left upper limb pain secondary to compression neuropathy,
reated with Pregabalin 150 mg  BD.
On  initial examination he was haemodynamically stable with
qual blood pressures of 157/84 mmHg  in both arms and a Glas-
ow Coma Scale (GCS) of 15. He was tender on light palpation of
he epigastric and umbilical areas but a pulsatile lesion could not be
alpated due to a degree of abdominal distension and body habitus.
here was no mucus, fresh blood or malaena on rectal examina-
ion. Erect chest X-ray did not show any evidence of perforated
iscera; however, ultrasound found an infra-renal abdominal aortic
neurysm with no identiﬁable free ﬂuid in the peritoneum.
Thoraco-abdominal computed tomography (CT) conﬁrmed the
resence of a 6 cm × 5.5 cm aortic aneurysm. A contained leak and
ssociated haematoma proximal to the right psoas muscle was also
dentiﬁed (Fig. 1i); as was a suspected migration of blood into the
uodenum (Fig. 1ii). The iliac arteries were noted to be patent but
arrowed bilaterally and atheromatous. Consequently, the patient
as deemed unsuitable for endovascular aneurysm repair (EVAR)
nd prepared for open surgical management.
During transfer to theatre, the patient developed haematemesis
nd melaena, but as blood loss was minimal and haemodynamic
tability maintained during anaesthetic induction, operative repair
roceeded.
Intra-operatively the aneurysm seemed mycotic in nature due
o its saccular and lobulated appearance (Fig. 2). An aorto-duodenal
stula was also noted and aneurismal specimens were collected for
ssessment. Surgical repair was performed using a 14 mm Gelsoft
raft pre-soaked in Rifampycin with insertion of a gastroduodenos-
omy drain and feeding jejunostomy.
Frank haematemesis on extubation necessitated a post-
perative tracheostomy. Ionotropes were commenced due to a
igniﬁcant drop in systolic blood pressure, the development of a
ompensatory tachycardia and increased oxygen requirement.
While  the harvested tissue did not demonstrate acid-fast bacilli,
xtensive caeseating necrosis, palisaded epitheloid granulomata
nd the presence of multinucleated giant cells were highly sug-
estive of tuberculosis.
The  patient underwent respiratory review 7 days post-
rocedure and was commenced on enteric anti-tuberculoid
reparations per jejunostomy. The following day, left abdominal
all cellulitis and worsening abdominal distension was observedFig. 2. Three-dimensional (3D) representation of the abdominal aortic aneurysm,
illustrating  its lobulated appearance.
with a signiﬁcant amount of draining faeculant ﬂuid and associated
leukocytosis (21.7 × 109/L).
Repeat abdominal CT showed a moderate amount of free ﬂuid in
the peritoneum and a disproportionately large amount of free gas
for the respective post-operative date; both ﬁndings suggestive of
perforation or anastomotic leak. The patient consequently under-
went laporotomy and insertion of a proximal loop jejunostomy.
Free gas and over 3 l of faeculant ﬂuid were found in the peritoneal
cavity and a leak at the feeding jejunostomy site was located. Per-
itoneal saline lavage was performed with insertion of pelvic-, left-
and right upper quadrant drains.
On return to the high dependency unit, the patient developed
acute renal failure and was commenced on haemoﬁltration. Oxy-
gen requirement again increased to 50% via tracheostomy and
chest X-ray showed bibasal consolidation. Ionotrope requirements
increased and renal function deteriorated further despite interven-
tion. Thirteen days post-operatively, the patient passed away.
3.  Discussion
BCG is a live attenuated strain of Mycobacterium bovis, rendered
anti-virulent by culture on a beef bile medium.4 It was ﬁrst used
as an instillation for superﬁcial bladder cancer in 1976 by Morales
et al.5 Since then it has become the preferred treatment for in situ
bladder carcinoma, immunoprophylaxis after resection of Ta/T1
disease, and for recurrent stage Ta disease, with response rates of
60–94% reported for early stage transitional cell carcinoma.4,5
BCG-instillation produces a localised inﬂammatory response in
the bladder but the exact mechanism of action is unclear. Recent
literature suggests the role of a mononuclear cell inﬁltrate and the
neutrophil-mediated release of tumour necrosis factor apoptosis
related ligand (TRAIL: Apo-2L).2
Intravesical BCG is a well-tolerated treatment. Adverse symp-
toms, including haematuria, bacterial cystitis, granulomatous
prostatitis, orchitis and epididymitis, tend to be localised and self-
limiting, although systemic reactions such as fever (2.9%), malaise,
hepatitis and pneumonitis (0.7%) are recognized.3,5 BCG-sepsis as
well as ocular and vascular complications such as abdominal aorticto BCG instillation have ruptured and necessitated emergency
surgery.4
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There are few documented cases of BCG-instillations causing
oth mycotic aneurysms and primary aortoenteric ﬁstulas. A 2009
iterature review of cases since 1975 found only 21 patients with
ycotic aneurysms attributable to BCG therapy.4 Aneurysms of
he abdominal aorta are most common, but aneurysms of other
rteries including femoral, popliteal and carotid arteries are also
ocumented.4
Furthermore, there are less than 20 documented cases of aor-
oenteric ﬁstulas following BCG infection, developing concurrently
r independently of mycotic aneurysms.5 Mortality rates over 50%
ave been documented for such ﬁstula development.6
Proposed mechanisms for the infection of vasculature by M.
ovis include haematogenous dissemination causing direct inti-
al  colonization (particularly after urological trauma at the time
f instillation), lymphatic spread in the retroperitoneum, or direct
xtension from an infected psoas abscess.3 Positive lung biopsies
nd sputum samples, alongside the retrieval of non-caeseating
ranulomas from bone marrow aspirates and liver biopsies in BCG
atients, supports the idea of haematological spread.7 Moreover,
 polysaccharide holotoxin consisting of glucose, heptose, glu-
osamine and galactosamine within the cell membrane of M. bovis
as been extracted and seen to increase vascular permeability and
nduce complement cascade activation.8
The classic triad of pulsatile mass, abdominal pain and fever
ay be present in a patient with a mycotic aneurysm secondary
o M.  bovis, but this is not always the case. The difﬁculty of iden-
ifying BCG on tissue samples complicates diagnosis further.3 The
old standard mycobacterial culture requires a minimum incuba-
ion period of 6–8 weeks while acid-fast stains require a minimum
f 10,000 organisms per gram of tissue to obtain a positive result.5
CG may  also be detected using PCR or inferred from the presence
f typical caseating granulomas.4
Management of complications resulting from BCG therapy can
e divided into that of the speciﬁc complication and that of
he BCG infection. With regard to mycotic aneurysms, surgical
ptions include in situ repair with a prosthetic graft, debridement
ith extra-anatomical bypass and, occasionally, endovascular stent
rafting.3 In our case, this was complicated by the aorto-enteric
stula.
Recommended medical therapy for systemic BCG infection is
soniazid, Rifampicin and Ethambutol (Pyrazinamide is not recom-
ended due to widespread resistance). Some advocate the addition
f corticosteroids, particularly for granulomatous hepatitis.5 While
he duration of anti-microbial therapy is a contentious issue, life-
ong therapy with periodic clinical evaluation and imaging studies
uch as CT, is advised in cases of in situ aortic reconstruction.3
. Conclusion
This case highlights the risks posed by BCG-instillation and
upports recommendations to safeguard against and monitor for
otentially life-threatening complications. Clariﬁcation is required
egarding duration of anti-tuberculous therapy and the impact
f concomitant anti-tuberculous medication on the therapeutic
ction of instillations.5 Long-term outcomes for patients post graft
epair for mycotic aneurysm are unknown and more research is
equired regarding the susceptibility of vascular grafts to mycobac-
erial infection.4
Recognition of the risks associated with BCG-instillations, even
n immunocompetent subjects, is paramount. The consideration of
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such effects in patients presenting to hospital even several months
or years after receiving BCG therapy is equally signiﬁcant.
5.  Learning points
• Intravesical  bacillus Calmette–Guerin (BCG) installation is a rec-
ognized  adjunct therapy with high response rates for early
bladder  cancer.
• Although an effective and generally well-tolerated treatment,
side-effects range from localised irritation to compromised vas-
cular wall integrity. These should be considered even several
months  or years after receiving BCG therapy.
• The  proposed mechanism of action of BCG incorporates TRAIL and
the recruitment of various immune mediators.
• There  is a need for review of current guidelines on anti-
tuberculous therapy as well as deﬁnitive recommendations
regarding long-term vascular surveillance for patients undergo-
ing  BCG therapy.
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